Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Expression of the cell surface receptor CD137 has been shown to enhance anti-cancer T cell function via engagement with its natural ligand 4-1BBL. CD137 ligation with engineered ligands has emerged as a cancer immunotherapy strategy, yet clinical development of agonists has been hindered by either t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yunqian, Qiu, Yangmin, Ding, Jie, Luo, Nana, Wang, Hao, Ling, Xiaomin, Sun, Jiya, Wu, Zhihai, Wang, Yisen, Liu, Yanpeng, Guo, Feifei, Sun, Ta, Shen, Wanwan, Zhang, Min, Wu, Dongdong, Chen, Bingliang, Xu, Wei, Wang, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569200/
https://www.ncbi.nlm.nih.gov/pubmed/34737267
http://dx.doi.org/10.1038/s41467-021-26645-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569200/
https://www.ncbi.nlm.nih.gov/pubmed/34737267
http://dx.doi.org/10.1038/s41467-021-26645-6

Ejemplares similares